Luspatercept Injection [Reblozyl]

DRUG2 trials

Sponsors

Groupe Francophone des Myelodysplasies, Associazione Qol-one

Conditions

AnemiaDel(5Q)MDSMyelodysplastic SyndromesTransfusion-dependent Anemia

Phase 1

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

RecruitingNCT05181735

Groupe Francophone des MyelodysplasiesMDS, Myelodysplastic Syndromes

Start: 2022-05-18End: 2029-06-19Target: 150Updated: 2026-03-05

Phase 2

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

RecruitingNCT05924100

Associazione Qol-oneAnemia, Del(5Q), Myelodysplastic Syndromes +1

Start: 2022-11-03End: 2029-12-03Target: 22Updated: 2024-11-18